Myrbetriq and Skin sensitisation - a phase IV clinical study of FDA data

Summary:

Skin sensitisation is found among people who take Myrbetriq, especially for people who are female, 60+ old, have been taking the drug for < 1 month.

The phase IV clinical study analyzes which people take Myrbetriq and have Skin sensitisation. It is created by eHealthMe based on reports of 28,270 people who have side effects when taking Myrbetriq from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.



On Feb, 07, 2023

28,270 people reported to have side effects when taking Myrbetriq.
Among them, 8 people (0.03%) have Skin sensitisation.


What is Myrbetriq?

Myrbetriq has active ingredients of mirabegron. It is often used in urge incontinence. eHealthMe is studying from 28,484 Myrbetriq users for its effectiveness, alternative drugs and more.

What is Skin sensitisation?

Skin sensitisation (sensitive skin) is found to be associated with 426 drugs and 278 conditions by eHealthMe.

Number of Myrbetriq and Skin sensitisation reports submitted per year:

Could Myrbetriq cause Skin sensitisation?

Time on Myrbetriq when people have Skin sensitisation *:

  • < 1 month: 100 %
  • 1 - 6 months: 0.0 %
  • 6 - 12 months: 0.0 %
  • 1 - 2 years: 0.0 %
  • 2 - 5 years: 0.0 %
  • 5 - 10 years: 0.0 %
  • 10+ years: 0.0 %

Gender of people who have Skin sensitisation when taking Myrbetriq *:

  • female: 75 %
  • male: 25 %

Age of people who have Skin sensitisation when taking Myrbetriq *:

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 0.0 %
  • 40-49: 0.0 %
  • 50-59: 0.0 %
  • 60+: 100 %

Common drugs people take besides Myrbetriq *:

  1. Vesicare: 5 people, 62.50%
  2. Lantus: 3 people, 37.50%
  3. Keppra: 3 people, 37.50%
  4. Zolpidem: 3 people, 37.50%
  5. Lasix: 3 people, 37.50%
  6. Lotemax: 3 people, 37.50%
  7. Melatonin: 3 people, 37.50%
  8. Biotin: 3 people, 37.50%
  9. Micardis: 3 people, 37.50%
  10. Novolog: 3 people, 37.50%

Common side effects people have besides Skin sensitisation *:

  1. Nasopharyngitis (inflammation of the nasopharynx): 5 people, 62.50%
  2. Fatigue (feeling of tiredness): 5 people, 62.50%
  3. Injection Site Swelling: 3 people, 37.50%
  4. Scar: 3 people, 37.50%
  5. Irritability: 3 people, 37.50%
  6. Muscle Strain (an injury to a muscle in which the muscle fibres tear): 3 people, 37.50%
  7. Injection Site Erythema (redness at injection site): 3 people, 37.50%
  8. Infusion Site Pruritus (severe itching at infusion site): 3 people, 37.50%
  9. Nasal Congestion (blockage of the nasal passages usually due to membranes lining the nose becoming swollen from inflamed blood vessels): 3 people, 37.50%
  10. Infusion Site Haemorrhage (bleeding from infusion site): 3 people, 37.50%

Common conditions people have *:

  1. Cardiac Disorder: 4 people, 50.00%
  2. Primary Immunodeficiency Syndrome: 3 people, 37.50%
  3. Swelling: 2 people, 25.00%
  4. Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 2 people, 25.00%
  5. Restless Leg Syndrome (a powerful urge to move your legs): 2 people, 25.00%
  6. Micturition Urgency (urgency to pass the urine): 2 people, 25.00%
  7. Bipolar Disorder (mood disorder): 2 people, 25.00%
  8. Pollakiuria (abnormally frequent passage of relatively small quantities or urine): 1 person, 12.50%

* Approximation only. Some reports may have incomplete information.

Do you take Myrbetriq and have Skin sensitisation?

Check whether Skin sensitisation is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.



Related studies

How severe was Skin sensitisation and when was it recovered:

Expand to all the drugs that have ingredients of mirabegron:

Alternative drugs to, pros and cons of Myrbetriq:

Common Myrbetriq side effects:

Browse all side effects of Myrbetriq:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Skin sensitisation treatments and more:

COVID vaccines that are related to Skin sensitisation:

All the drugs that are associated with Skin sensitisation:

All the conditions that are associated with Skin sensitisation:

How the study uses the data?

The study uses data from the FDA. It is based on mirabegron (the active ingredients of Myrbetriq) and Myrbetriq (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: